Skip to content
TaiRx, Inc. | New Drug Development Logo TaiRx, Inc. | New Drug Development Logo TaiRx, Inc. | New Drug Development Logo
  • About Us
    • Meet TaiRx
    • Vision
    • Innovation
    • Management Team
    • Scientific Advisory Committee
    • Board of Directors
  • Product Pipeline
    • CVM-1118
    • Zelnite®
    • TRX-NOC
    • TRX-920
    • TRX-105
  • Market Product
  • News
  • Contact Us
  • enEnglish
    • zh-hant繁體中文
News jeff 2018-05-31T11:46:02+00:00

News

A major milestone for cancer drug development in Taiwan! CVM-1118 approved by the US FDA to start Phase II clinical study in the US.

2018/4/15 TaiRx’s CVM-1118 [...]

Chang Lisa 2021-03-11T16:39:29+00:00 April 15th, 2018|News|
Read More

A first in Taiwan! In collaboration with Taiwanese API and drug product manufacturers, TaiRx produced the first domestically manufactured selenium trace element drug in Taiwan and was approved by the Taiwan FDA.

2018/3/8 TaiRx, Inc. [...]

Chang Lisa 2021-03-11T15:36:59+00:00 March 8th, 2018|News|
Read More

TaiRx published study results of serum GPx-3 protein levels and associated bioactivity in healthy subjects and sepsis patients in Clinica Chimica Acta.

2017/10/31 Lee WJ, Chen YL, Chu YW, Chien [...]

Chang Lisa 2018-06-04T17:52:42+00:00 October 31st, 2017|News|
Read More

TaiRx and Northwestern University Ann & Robert H. Lurie Children’s Hospital completed exclusive licensing deal for global development and market rights using Nodal protein as new biomarker to detect malignant tumor also for the treatment of various metastatic cancer.

2017/8/22 TaiRx Announces [...]

Chang Lisa 2018-06-04T17:50:31+00:00 August 22nd, 2017|News|
Read More

TaiRx held a pre-IPO institutional investors’ conference and announced the listing on Taiwan Emerging Market on the 20th of June.

2017/6/15 TaiRx shows its [...]

Chang Lisa 2018-06-04T17:50:50+00:00 June 15th, 2017|News|
Read More
Previous234Next
Copyright© 2018 台睿生物科技股份有限公司 | 網頁設計公司:振作國際